Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2686 to 2700 of 9071 results

  1. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTG10886 Expected publication date:  04 February 2027

    HealthTech guidance
    In development

  2. Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over

    Awaiting development Reference number: GID-TA12446 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  23 February 2027

    NICE guideline
    In development

  4. Glofitamab for treating relapsed or refractory mantle cell lymphoma

    Awaiting development Reference number: GID-TA12447 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Dabrafenib with trametinib for treating BRAF V600E mutation-positive advanced differentiated thyroid cancer after radioactive iodine and 1 or 2 VEGFR-targeted treatments

    Awaiting development Reference number: GID-TA12461 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Technologies for diagnosing endometriosis in primary care: early use assessment

    In development Reference number: GID-HTG10877 Expected publication date:  08 October 2026

    HealthTech guidance
    In development

  7. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  14 July 2026

    Technology appraisal guidance
    Awaiting development

  8. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  10. Miniature lens system implantation for advanced age-related macular degeneration

    In development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    In development

  11. Urinary biomarker tests to detect bladder cancer

    Awaiting development Reference number: GID-HTG10903 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716

    In development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 6 July 2026.

    In consultation

  14. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  15. Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma

    In development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    In development